Abstract

Molecular imaging techniques such as PET and SPECT have been used to shed light on how coronavirus disease 2019 (COVID-19) affects the human brain. We provide a systematic review that summarizes the current literature according to 5 predominant topics. First, a few case reports have suggested reversible cortical and subcortical metabolic alterations in rare cases with concomitant para- or postinfectious encephalitis. Second, imaging findings in single patients with the first manifestations of parkinsonism in the context of COVID-19 resemble those in neurodegenerative parkinsonism (loss of nigrostriatal integrity), but scarceness of data and a lack of follow-up preclude further etiologic conclusions (e.g., unmasking/hastening of neurodegeneration vs. infectious or parainfectious parkinsonism). Third, several case reports and a few systematic studies have addressed focal symptoms and lesions, most notably hyposmia. The results have been variable, although some studies found regional hypometabolism of regions related to olfaction (e.g., orbitofrontal and mesiotemporal). Fourth, a case series and systematic studies in inpatients with COVID-19–related encephalopathy (acute to subacute stage) consistently found a frontoparietal-dominant neocortical dysfunction (on imaging and clinically) that proved to be grossly reversible in most cases until 6 mo. Fifth, studies on post–COVID-19 syndrome have provided controversial results. In patients with a high level of self-reported complaints (e.g., fatigue, memory impairment, hyposmia, and dyspnea), some authors found extensive areas of limbic and subcortical hypometabolism, whereas others found no metabolic alterations on PET and only minor cognitive impairments (if any) on neuropsychologic assessment. Furthermore, we provide a critical appraisal of studies with regard to frequent methodologic issues and current pathophysiologic concepts. Finally, we devised possible applications of PET and SPECT in the clinical work-up of diagnostic questions related to COVID-19.

Highlights

  • Neurological complications (1) and neurocognitive aftermaths (2) are frequently described in Corona Virus Disease 2019 (COVID-19) which is caused by an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

  • We devised possible applications of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) in the clinical work-up of diagnostic questions related to COVID-19

  • When using a liberal threshold (p

Read more

Summary

INTRODUCTION

Neurological complications (1) and neurocognitive aftermaths (2) are frequently described in Corona Virus Disease 2019 (COVID-19) which is caused by an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The term “Post-COVID-19 syndrome” in its strict sense (5) is detached from particular symptoms, it is widely used as a label for a syndrome enveloping lasting fatigue, cognitive problems and shortness of breath which affect approximately 10% of all patients (2,19). COVID-19 may unmask subclinical neurodegenerative disorders or worsen preexisting conditions Molecular imaging techniques such as positron emission tomography (PET) and singlephoton emission computed tomography (SPECT) have been used for the diagnostic work-up of neurological COVID-19 manifestations. These examinations provided a plethora of sometimes conflicting results in highly variable populations that are often ill-defined in terms of symptoms and temporal course. We provide a preliminary suggestion on possible future use of PET and SPECT in this particular field of application based on the literature and our personal experience

MATERIALS AND METHODS
Major Findings
Major Findings thalamus
Analysis Findings
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call